Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma

NCT02259231 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02259231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02259231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma
Lead sponsor
Biogen
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2014
Completion date
July 23, 2018
Enrollment
41 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, metastatic (stage iv) melanoma, unresectable (stage iii) melanoma